2型重度哮喘中的代谢组学、微生物群以及体内和体外生物标志物：一篇观点综述
Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review.
作者信息
Caruso Cristiano, Colantuono Stefania, Nicoletti Alberto, Arasi Stefania, Firinu Davide, Gasbarrini Antonio, Coppola Angelo, Di Michele Loreta
机构信息
Allergy Unit, Fondazione Policlinico A. Gemelli, IRCCS, Catholic University of the Sacred Heart, 00100 Rome, Italy.
Digestive Disease Center, Medical and Surgical Sciences Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Sacred Heart, 00100 Rome, Italy.
出版信息
Metabolites. 2021 Sep 22;11(10):647. doi: 10.3390/metabo11100647.
Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient; thus, it could be a new approach for the management of severe asthma that considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. Metabolomics is the systematic study of low molecular weight (bio)chemicals in a given biological system and offers a powerful approach to biomarker discovery and elucidating disease mechanisms. In this point of view, metabolomics could play a key role in targeting precision medicine.
精准医学是指根据每位患者的个体特征量身定制治疗策略；因此，它可能是一种管理重度哮喘的新方法，该方法考虑了基因、环境暴露和生活方式方面的个体差异。精准医学还将帮助医生选择正确的治疗方法、最佳给药时间，从而尽量提高药物疗效，并有可能减少不良事件。代谢组学是对给定生物系统中低分子量（生物）化学物质的系统研究，为生物标志物发现和阐明疾病机制提供了一种强有力的方法。从这一角度来看，代谢组学在靶向精准医学中可能发挥关键作用。
Zotero 插件